Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181737 | 0.84 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL4175180 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4171624 | 0.82 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4181587 | 0.81 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4175856 | 0.81 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4175679 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4173436 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 | |
| SCHEMBL4182135 | 0.81 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL4181940 | 0.81 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4183694 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TAAR1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | FHIT, CYP3A43, DNPEP | NPC1 2016/4885RAB9A 4846/4885SMN1; SMN2 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.